Living with Crohn's disease can be a daily struggle, filled with pain and uncertainty. Many patients find that current treatments either don't work or lose their effectiveness over time, leaving them searching for new solutions. This study is investigating a combination of two promising drugs, vedolizumab and either adalimumab or ustekinumab, to see if they can provide better relief for adults with moderate to severe Crohn's disease. Participants will first receive the combination treatment, and those who respond will continue with vedolizumab alone. The goal is to assess how well these treatments work in reducing inflammation in the intestines, which is a key factor in managing Crohn's disease. If these new combinations prove effective, they could offer hope to many patients who feel stuck in their current treatment journey. However, it's important to remember that this is still a study, and results will take time to analyze. For now, the potential for better options is on the horizon, bringing a glimmer of hope to those affected by this challenging condition.
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic ResponseCan New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider dual therapy with vedolizumab for Crohn's patients unresponsive to prior treatments.
This Phase 4 study evaluates the efficacy and safety of vedolizumab in combination with either adalimumab or ustekinumab in adults with moderate to severe Crohn's Disease. The study is structured in two parts: Part A involves dual targeted therapy, while Part B involves vedolizumab monotherapy for those who respond in Part A. The primary endpoint is the percentage of participants achieving an endoscopic response, as measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD), at Week 26 for Part A and at Week 52 for Part B. Participants are categorized into cohorts based on prior treatment responses, including those with inadequate response to IL antagonists, TNF inhibitors, or Janus kinase inhibitors. The study aims to enroll 100 participants, with an estimated primary completion date in June 2027. Safety and adverse events will be monitored throughout the study, although specific safety data are not yet available. This trial could provide insights into the efficacy of dual targeted therapy in this patient population.
What this means for you:
New drug combinations may soon provide hope for better Crohn's disease management and relief. More on Crohn's Disease
FDA Approves Hadlima (adalimumab) for Multiple Inflammatory Indications
FDA approves Hadlima, a new biosimilar for several inflammatory diseases.
The FDA approved Hadlima (adalimumab) for several inflammatory conditions including rheumatoid arthritis, juvenile idiopathic arthritis, pso…
The FDA approved Hadlima (adalimumab) for treating conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. It is a biosimilar,…
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease
Chronic cell aging may drive scarring in Crohn's disease
This systematic review examines the role of cellular senescence in intestinal fibrosis within Crohn's disease. The authors conclude that acu…
New research reveals how the timing of cellular aging determines whether your body heals properly or develops harmful scar tissue.
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE4
Condition(s): Crohn's Disease
Intervention(s): Vedolizumab (DRUG), Adalimumab (DRUG), Ustekinumab (DRUG), Ustekinumab (DRUG)
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment.
The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A.
Each participant will be followed up for at least 26 weeks after the last dose of treatment.
Detailed: The drug being tested in this study is vedolizumab. Vedolizumab is being tested to treat people with moderate to severe Crohn's disease who have experienced inadequate response, loss of response or intolerance to either one prior interleukin \[IL\] antagonist, and no other biologic/small molecule (Group A); one IL antagonist and either one Janus kinase inhibitor (JAKi) or one TNFi (other than adalimumab) \[Group B\] (Cohort 1) or one prior tumor necrosis factor inhibitor \[TNFi\] and no other biologic/small molecule (Group C); one TNFi and either 1 JAKi or one IL antagonist (other than UST) (Group D) (Cohort 2). The study will look at the efficacy and safety of dual targeted therapy.
The study will enroll approximately 100 participants. Participants will be assigned to one of the two trea
Primary Outcome(s): Part A: Percentage of Participants With an Endoscopic Response Based on the Simple Endoscopic Score for (SES-CD) at Week 26; Part B: Percentage of Participants With an Endoscopic Response Based on the SES-CD at Week 52
Enrollment: 100 (ESTIMATED)
Lead Sponsor: Takeda
Start: 2024-04-18 | Primary Completion: 2027-06-28
Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis
TyG Index Linked to Higher Fatty Liver Risk
Related in Gastroenterology
Acupuncture modulates the microbiota-gut-brain axis to remodel microbial structure in patients with irritable bowel syndrome
Acupuncture May Help Manage Irritable Bowel Syndrome Symptoms
This systematic review examines how acupuncture influences the microbiota-gut-brain axis in patients with irritable bowel syndrome. The auth…
New research suggests acupuncture may help manage irritable bowel syndrome by improving gut bacteria and balancing the gut-brain connection.
Reduced Shannon index indicates lower alpha-diversity in the gut microbiota of patients with primary biliary cholangitis
Gut Microbiota Differences Linked to Primary Biliary Cholangitis
This meta-analysis of 1,057 participants found that patients with primary biliary cholangitis have significantly lower Shannon index values …
A large review of patient data shows that people with primary biliary cholangitis have significantly lower gut bacterial diversity than heal…
Probiotic supplementation may improve salivary buffering and reduce cariogenic bacteria
A review of six studies shows probiotics may help oral and gut health in people
This systematic review of 6 reviews suggests probiotic supplementation may improve salivary buffering capacity and plaque pH, reduce Strepto…
This review looked at six studies on probiotic supplements. Results suggest better saliva function and fewer bad mouth bacteria, though stud…
Balloon-assisted ESD shows comparable outcomes to conventional ESD for colorectal polyps
Balloon-assisted endoscopic submucosal dissection shows shorter procedure time in RCTs
This systematic review and meta-analysis of 1449 patients found that balloon-assisted endoscopic submucosal dissection (BA-ESD) and conventi…
A meta-analysis of 1,449 patients found balloon-assisted endoscopic submucosal dissection had shorter procedure times in randomized trials, …
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …